Velox Biosystems, a startup that has graduated from the Cove incubator program and moved into a new lab in Irvine, has successfully closed their pre-Series A funding round with Decheng Capital. A highly respected and sought-after VC in Velox’s market space, Decheng will serve as a partner to help the company position itself for the next stage of growth and lead the Series A round for Velox. Additional highlights from the Velox team include completing the C-corp conversion, adding a Board of Directors, setting up the Incentive Stock Option plan, and expanding their team to keep up with the rapid growth.